MAP2K1 and thyroid gland carcinoma: The aberrant activation of RAS-BRAF-MEK1/2-ERK1/2 kinase signaling pathway, which mediates the extracellular signals into the nucleus, contributes to thyroid carcinoma by increasing cell proliferation, survival, and metastasis.